Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genprex ( (GNPX) ) has issued an announcement.
On March 18, 2026, Genprex announced that its collaborators will present multiple posters at the 2026 American Association for Cancer Research Annual Meeting in San Diego, highlighting new preclinical data on Reqorsa gene therapy for lung cancer. The first study identified TROP2 and PTEN expression patterns as potential biomarkers of primary resistance to TUSC2 gene therapy in NSCLC models, suggesting a way to better select patients and tailor treatment strategies.
A second study in ALK-positive NSCLC cell, organoid, and mouse models showed that Quar Oze-mediated TUSC2 overexpression induces strong apoptosis and enhances the effect of the ALK inhibitor alectinib, including in models with acquired alectinib resistance. The combination therapy produced greater tumor shrinkage and survival benefits than alectinib alone, underscoring Reqorsa’s potential role as an adjunct treatment in resistant disease.
A third study demonstrated that restoring TUSC2 function with Quar Oze in mouse tumor models enhances natural killer cell cytotoxicity, increases antitumor immune activity, and in many cases drives complete tumor regression. These findings position TUSC2 as both a tumor suppressor and immunomodulatory target, reinforcing the rationale for advancing Reqorsa as a dual-function therapeutic in future clinical development for lung cancer.
More about Genprex
Genprex, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for cancer, with a lead program centered on its Reqorsa (quaratusugene ozeplasmid, or Quar Oze) TUSC2 gene therapy for non-small cell lung cancer. The company works with academic and research collaborators to generate preclinical and clinical data that can support the advancement of its oncology pipeline and improve patient selection in targeted lung cancer indications.
Average Trading Volume: 1,045,913
Technical Sentiment Signal: Sell
Current Market Cap: $4.68M
For detailed information about GNPX stock, go to TipRanks’ Stock Analysis page.